Sandoz Launches Japan's First Biosimilar; Sees Huge Market Potential In Japan
This article was originally published in PharmAsia News
Executive Summary
Novartis's generic subsidiary Sandoz launched recombinant human growth hormone somatropin in Japan. Approved in June with the same indications as Pfizer's Genotropin (somatropin), Sandoz's somatropin marks the first biosimilar launch and the company looks to further generic launches in Japan
You may also be interested in...
Mexico And Brazil Release Biosimilars Guidelines, But Not All Issues Resolved
Mexico published its final biosimilars guidelines the same day as India, both drawing from WHO standards.
Merck Eyes Emerging Biosimilars Market In Japan
Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012
Merck Eyes Emerging Biosimilars Market In Japan
Merck is the latest major drug maker to leap into the Japanese generics foray, as the Whitehouse Station, NJ-based company announced plans to launch its first biosimilar drug for anemia in Japan as early as 2012